Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
CA 2507765 C · Owner: Dompe S.P.A. · Inventors: Bertini, Riccardo; Colotta, Francesco; Cesta, Maria Candida
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The compounds of formula (I): where Ar is an aromatic ring and Ra Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL- 8, such as psoriasis, rheumatoid arthritis ulcerative cholitis and for the , treatment of damages caused by ischemia and reperfusion.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 9, 2003 and granted March 20, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 9, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 9, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.